Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

NCT05304962 is registered in ClinicalTrials.gov with Regor Pharmaceuticals Inc. as lead sponsor.

NCT NCT05304962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Lead sponsor
Regor Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 4, 2022
Completion date
March 31, 2027
Enrollment
64 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer